Tempus AI (NASDAQ:TEM) Reaches New 1-Year Low – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $41.46 and last traded at $41.4930, with a volume of 613604 shares changing hands. The stock had previously closed at $42.91.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Jefferies Financial Group assumed coverage on shares of Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a report on Monday, July 20th. Wolfe Research assumed coverage on Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research report on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $68.92.

Tempus AI Trading Down 0.6%

The stock has a 50-day moving average of $51.63 and a 200 day moving average of $53.30. The stock has a market cap of $7.66 billion, a PE ratio of -24.74 and a beta of 3.46. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. During the same quarter in the prior year, the company earned ($0.24) EPS. Tempus AI’s quarterly revenue was up 36.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Ryan Fukushima sold 33,284 shares of Tempus AI stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the transaction, the chief executive officer owned 167,763 shares of the company’s stock, valued at approximately $9,627,918.57. The trade was a 16.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 8,703 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the transaction, the executive vice president owned 128,215 shares of the company’s stock, valued at approximately $5,650,435.05. This trade represents a 6.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 449,793 shares of company stock worth $23,248,231. Insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares during the period. ARK Investment Management LLC lifted its position in shares of Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the last quarter. Finally, Amova Asset Management Americas Inc. boosted its stake in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.